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Summary The objective of this paper is to compare the hospital costs of treating patients with colorectal
cancers detected as a result of a faecal occult blood screening programme with those of patients whose cancers
present symptomatically (control group). Patient-specific cost estimates are made, using case records and
hospital accounts, for 360 patients over 3 years. Mean treatment costs for the group offered screening and for
the control group are calculated to be £3,179 and £2,966 respectively, although the difference between these
means is insignificant. Low treatment costs in the case of screen-detected cancers are largely accounted for by
polypectomy with no subsequent readmission; in the control group case, they tend to be accounted for by
early patient death. For the sample as a whole, the costs of treating very early-, and very late-, stage cancer are
significantly lower than those of treating cancers in the intermediate stages. On the basis of trial evidence, the
introduction of mass screening for colorectal cancer is unlikely to give rise to substantial economies in the
costs of treatment.
Mass population screening for colorectal cancer is currently
being evaluated concurrently in several countries, by means
of randomised controlled trials (Miller et al., 1991). The
largest of these in terms of subject recruitment is that being
undertaken at the University Hospital, Nottingham, UK.
The Nottingham trial was initiated in 1981 and has now
attained its recruitment target of 155,000 subjects, random-
ised into study and control groups of equal size.
Patients with advanced colorectal cancer typically present
with symptoms such as acute pain and poor bowel function-
ing, owing to constriction caused by the growth of the
tumour on and into the bowel wall. At the early, pre-
symptomatic phase, however, tumours tend not to obstruct
noticeably, although they are likely to bleed and to deposit
minute quantitites of blood in the stool. Such deposits cannot
be observed visually but they can be detected chemically. The
study group has been offered the self-administered Haemoc-
cultTM faecal occult blood (FOB) test every 2 years. Pea-size
stool samples are taken on three successive days, smeared
onto guaiac-impregnated paper, and the completed test is
returned to the processing laboratory. The addition of a
reagent produces a characteristic colour change if occult
blood is present in the stool sample, such as reaction being
suggestive of a bleeding and possibly malignant neoplasm in
the colon or rectum. Subjects with positive test results pro-
ceed to endoscopic or radiological investigation. The subject
compliance rate to 1989 averaged 57.8% for the initial test
and 77.0% for the first re-test. Patients with screen-detected
and symptomatic-presenting cancers in both groups have
been followed up fully (Hardcastle et al., 1983; 1989). The
trial will involve five complete screening rounds for all sub-
jects and is thus expected to continue into the late-1990s.
Economic appraisal forms an important component in the
evaluation of any cancer screening programme. The initial
concern of the economic appraisal of the Nottingham trial
was the examination of the cost implications of differing
screening protocols, i.e. the costs of detecting colorectal
cancer by screening (Walker et al., 1991a; Whynes et al.,
1992). The present paper, however, compares the National
Health Service hospital costs of treating cancers both detect-
ed and presenting in the study and control groups. In partic-
ular, it addresses the hypothesis that, because screening will
result in more cancers being detected at the earlier stages of
the disease, average treatment costs under a screening regime
should be correspondingly lower. Early detection, it has been
argued, should increase the potential for low-cost endoscopic
treatment (polypectomy) to be used in place of high-cost
resection. A higher proportion of curative procedures on
early-stage cancer would be expected to lower the costs of
treating recurrent disease. Empirical studies from the USA
(Allison & Feldman, 1985; Barry et al., 1987; Eddy et al.,
1987; Neugut & Forde, 1988), based on follow-up periods of
up to 5 years, have produced differences in treatment costs
between early- and late-stage cancers of up to 100%. In its
major review of screening cost-effectiveness, the US Office of
Technology Assessment opted for an 'average' cost premium
of 50% for treating late-stage, as opposed to early-stage,
cancer (Wagner et al., 1990).
Method
Although some colorectal cancer patients have their cancers
treated successfully by means of a single operation, many
others subsequently return to the hospital for treatments
related to complications of the initial intervention or cancer
recurrence. The cost of the initial episode of treatment, there-
fore, is likely to be an underestimate of the true hospital cost
implications of colorectal cancer treatment. To assess the
economic impact of the disease more fully, treatment costs
for each patients were calculated over a 3-year period (or
until death, if occurring within this period), starting from the
date of diagnosis in each case. The choice of 3 years as a
cut-off point was dictated by (i) the need to generate a
sample of sufficiently large size to permit statistical inference,
(ii) clinical findings, which suggest that the majority of com-
plications and cancer recurrences are likely to occur within
1-2 years of the initial intervention (Pollard et al., 1989).
To July 1991, 360 trial patients met the 3-year follow-up
criterion. All were treated by surgical interventions alone.
The hospital notes of these patients provided the primary
data for the costing study, yielding information on types of
diagnostic investigation performed, lengths of inpatient stay
(including intensive care), duration and types of operations,
radiology, pathology and ECG requests. The majority of
these categories of data may be directly translated into costs
using the University Hospital's financial returns. Exceptions
are the costs of the various diagnostic techniques and the
daily cost of intensive care. The former had already been
estimated in an earlier study (Walker et al., 1991b); for the
latter, a proportional 'mark-up' over normal inpatient day
costs was employed, estimated from other empirical studies
of intensive care (Shiell, 1991). All estimated costs are mar-
ginal costs and are expressed at 1990-91 prices. Costs of
routine follow-up have not been included although it should
be noted that the follow-up protocol is identical in both the
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study and the control group cases. In consequence, no bias
should be imparted as a result of this omission.
The University Hospital is a major teaching and research
centre, and hence procedures related to research were omitted
from the cost estimates wherever possible. For example, a
comparative trial of pre-operative methods of imaging rectal
cancer was in progress during part of the study period: all
resources used as a result have been excluded. Only treatment
costs related directly to colorectal cancer were included in the
3-year post-diagnosis follow-up period.
Results
Study group cancers may be divided into three categories: (i)
those detected in patients as a result of their acceptance of
the offer of FOB screening (screen-detected cases), (ii) those
presenting in patients either who did not respond or who
refused the offer of screening (no-response cases), (iii) those
presenting between screening rounds in patients who had
previously recorded a negative FOB test (interval cases).
Table I presents the numbers of cancers for the control
group and for each of the study group categories. As may be
inferred, the cancer yield was 37% higher in the study group
compared with the control group. The table also displays the
mean treatment costs for patients, divided into five time
periods:
(i) costs relating to the initial investigation and diagnosis;
(ii) pre-operative costs, incurred between admission to
hospital and the initial, main operation;
(iii) the costs of the main treatment or operation, up to the
time of first discharge;
(iv) costs incurred as a result of any short-term subsequent
re-admission, for the purpose of completing the main
operation or dealing with complications arising there-
from;
(v) other cancer-related treatment costs incurred between
discharge from re-admission and 3 years post-diag-
nosis (or death).
Figure 1 portrays total costs as frequency distributions.
Statistical comparisions of means between the control
group and the three study sub-groups for each cost category
indicate no significant differences (t-test at 5%), with three
exceptions; first, the difference between investigation costs for
screen-detected cancers and controls (£47, confidence inter-
vals £25 to £69), second, the difference between main treat-
ment cost for screen-detected and no-response cases (£610,
confidence intervals £111 to £1,109), third, the difference
between total cost for screen-detected and no-response cases
(£959, confidence intervals £249 to £1,669).
From the data on individual patients, those with low
treatment costs were identified ('low' defined as costs less
than or equal to one standard deviation below the mean for
the relevant cost distribution). Within the control group,
there were 14 such cases. Of these, four patients underwent
polypectomy and three survived to the end of the 3-year
follow-up period. The remaining 10 patients died, seven
before or during the first admission and the remaining three
within 6 months of diagnosis. For the no-response group
seven of the 12 died at or before the time ofadmission, and a
Table I Mean treatment cost (£) per case (standard deviation)
Control Study
Screen-
All detected Interval No-response
n= 152 208 77 26 105
Investigation 90 (84) 104 (89) 137 (73) 75 (71) 87 (96)
Pre-operative 162 (477) 125 (568) 75 (165) 47 (123) 180 (781)
Main treatment 2050 (2009) 2051 (1624) 1734 (948) 1807 (831) 2344 (2054)
Re-admission 107 (457) 194 (603) 155 (494) 309 (1104) 194 (485)
Other 557 (1172) 705 (1402) 519 (1252) 973 (1921) 775 (1336)
Total 2966 (2418) 3179 (2526) 2621 (1914) 3211 (3086) 3580 (2684)
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Table II Average total cancer treatment costs by Dukes' stage (£)
A B C D
Screen-detected, n = 39 18 15 5
Mean total cost (s.d.) 1874 (1349) 2749 (1207) 3978 (2665) 3912 (2007)
Interval cases, n = 7 4 7 8
Mean total cost (s.d.) 2704 (1976) 2005 (454) 5316 (4672) 2415 (1694)
No-response, n = 14 36 19 36
Mean total cost (s.d.) 3776 (4239) 3648 (2318) 4283 (1760) 3063 (2543)
Study group, n = 60 58 41 49
Mean total cost (s.d.) 2414 (2542) 3256 (2021) 4348 (2824) 3044 (2402)
Control group, n = 15 42 49 43
Mean total cost (s.d.) 2523 (2103) 3224 (1570) 3289 (1826) 2508 (3437)
Combined, n = 75 100 90 92
Mean total cost (s.d.) 2436 (2461) 3242 (1845) 3771 (2393) 2793 (2944)
further two died within 6 months. One patient underwent
polypectomy and two underwent local excision; all three
survived for 3 years. For the screen-detected cases, nine out
of the 11 patients underwent polypectomy, with the remain-
ing two undergoing local excision, and none were re-admitted.
Ten of these patients survived for the 3-year follow-up
period, the eleventh surviving 2.5 years. No interval case had
a cost less than one standard deviation below the mean of
the distribution.
The severity of colorectal cancer is conventionally assessed
by Dukes' staging, ranging from A (cancers penetrate into
but not through the bowel wall) to the most severe stage, D
(unresectable local tumours or distant spread). Table II dis-
plays average treatment cost by stage (note that three cancers
in the control group were unstaged). Between the study and
control groups, only the difference in stage C costs is
significant (£1,059, confidence intervals £81 to £2,037). The
proportion of stage A cancers in the study group (28.8%) is
significantly higher than the proportion in the control group
(9.9%) (2= 19.18; P<0.001). Correspondingly, the propor-
tion of stage C cancers is significantly lower (19.7 compared
with 32.2%) (X2 = 7.34; P<0.01).
For the combined sample, the difference in costs between
stage A and stage B cancers is significant - £806, confidence
intervals £162 to £1,450 (t-test at 5%). Likewise, the differ-
ence in costs between stage C and stage D cancers is signi-
ficant - £978, confidence intervals £186 to £1,766. However,
the costs of treating stage A cancer are not significantly
different from those of treating stage D, and both are signi-
ficantly different from the cost of treating stages B and C.
Defining early-stage cancer as A and B, and late-stage as C
and D (as do the studies cited above), we obtain a mean cost
for the former of £2,897 (s.d. 2,174) and, for the latter, of
£3,277 (s.d. 2,737). The difference between these means is
insignificant (t-test, P>0.1).
Discussion
On the basis of the Nottingham evidence presented above, we
find no support for the hypotheses that the cost of treatment
for early-stage cancer is less than the cost of treating the
late-stage counterpart over a 3 year period.
The clear discrepancy between our finding and that of the
cited US studies requires some words of explanation, and
there exist several possibilities in this respect. First, in some
instances, US results have been based on exceptionally small
samples, as low as 13 cancers in total in one case (Allison &
Feldman, 1985). Those findings, accordingly, may be prone
to small sample bias. Second, in none of the cited US cases
had recruitment occurred via a randomised controlled trial,
suggesting a prior selection of subjects according to some
other criterion (for example, membership of a specific insur-
ance plan). This might represent a source of selection bias.
Perhaps most important of all, the costs used in the US
evaluations are not, technically speaking, costs at all; they are
charges or prices levied by (mostly) private hospitals and
accepted as valid by the financial institutions responsible for
payment (Finkler, 1982). Evidence suggests that the intensity
and duration of hospital treatment for colorectal cancer in
the USA (which is the principal determinant of total costs)
varies with the nature of the patient's health insurance pack-
age (Heine & Rothenberger, 1991). Different packages thus
permit hospitals to levy different charges on their customers.
As charges result from bargaining between hospitals and
insurers, they bear no clear relationship to actual resource
usage during treatment. It is therefore quite probable that the
US price differential between early- and late-stage cancer
treatment arises as much from a negotiated agreement
between care suppliers and purchasers as it does from any
differential use of inputs.
By far the largest cost component over the 3 year period is
the main treatment episode, 65 and 69% in the study and
control groups, respectively. Although polypectomy offers the
principal hope for economies in treatment costs resulting
from screening, in only 15 cases did simple polypectomy
represent the sole treatment episode (ten screen-detected, one
no-response, four controls). All of these cases were stage A
cancers, with a mean treatment cost of £257 (s.d. 142).
However, the fact that a cancer is at a very early stage or
confined within a polyp does not guarantee that treatment
can be effected successfully by polypectomy alone (Langer et
al., 1984; Morson et al., 1984; Russell et al., 1990), nor does
it preclude the possibility of recurrence at a later stage (Lotfi
et al., 1986). Indeed, the remaining stage A cancers in the
combined sample (80%) all required resections at a higher
cost, although at a lower cost than that necessitated by the
treatment of stages B and C cancers. In six cases, re-
admission occurred, after-care was required in nine cases,
whilst seven patients experienced both re-admission and
after-care.
It is evident that any treatment cost advantage which
might have been anticipated as a result of screening has been
substantially eroded by the high costs incurred by the no-
response group. The proportion of costs per case in excess of
£5,000 is considerably higher for this group than for both
control and screen-detected cases (21.0%, compared with
11.2 and 10.4% respectively). The reasons for this cost differ-
ence are, at present, unclear. From the results, it is possible
that cancers in no-response cases are more difficult to treat or
that no-response patients are worse affected by both disease
and treatment.
Conclusions
Accepting the Nottingham finding, it accordingly follows that
substantial economies in treatment costs during the 3 years
following initial diagnosis should not be anticipated follow-
ing the implementation of a colorectal cancer screening pro-
gramme. This is because detection at early-, as opposed to
late-, stage appears to make no significant difference to hos-
pital treatment costs. Indeed, if one were to argue that a
screening programme would detect a cancer at the asympto-
matic early stage some years in advance of detecting it symp-
tomatically at the late stage, then the discounted treatment
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cost would actually be higher under the screening scenario.
Sizeable treatment cost economies as a result of screening
would only become evident if the staging distribution were to
be 'rolled forward' such that the proportion of specifically
stage A cancers came to dominate the total. Such a situation
could only be envisaged under the assumptions that the
programme were to be screening for incident cancers only,
and had high sensitivity and compliance rates.
This result, however, should not be taken to pre-judge the
cost-effectiveness, or otherwise, of such a programme. From
the evidence presented, it is reasonable to conclude that the
principal explanation of low treatment cost in the screen-
detected cases is cheap and successful initial intervention. By
contrast, the explanation for low cost in other categories is
early patient death, obviating the need for treatment. There
are already evidence from other sources that expected survival
gains are strongly correlated with cancer stage at diagnosis
(Jatzko et al., 1992), and it is expected that the Nottingham
trial will also demonstrate such gains when its survival results
are eventually published. The implication is that, whilst treat-
ment costs may presently show no differences under a screen-
ing vs a non-screening scenario, outcome benefits are likely to
be superior under the former, given the difference in the
staging distribution. Although important, treatments costs
are only one element in the cost-effectiveness equation which
remains to be fully identified.
The research was conducted within the Nottingham colorectal cancer
screening trial, supported principally by the Medical Research Coun-
cil.
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